Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers

Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers

Five-year event-free survival in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) currently exceeds 80–85%. However, 15–20% of patients still experience a relapsed/refractory disease. From 1 January 2015 to 31 December 2020, thirty-nine patients, 0–21 years old with r/r BCP-ALL were...

Full description

Bibliographic Details
Main Authors: Giuliana Beneduce, Antonia De Matteo, Pio Stellato, Anna M. Testi, Nicoletta Bertorello, Antonella Colombini, Maria C. Putti, Carmelo Rizzari, Simone Cesaro, Monica Cellini, Elena Barisone, Fara Petruzziello, Giuseppe Menna, Rosanna Parasole
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
targeted therapy
acute lymphoblastic leukemia
pediatric
relapse
toxicity
real-life experience
Online Access:https://www.mdpi.com/2072-6694/14/2/426

Similar Items

Similar Items